Evaluation of flurbiprofen urinary ratios as in vivo indices for CYP2C9 activity

British Journal of Clinical Pharmacology

Volumn 63, Issue 4, 2007, Pages 477-487

  Zgheib, N K ^a   Frye, R F ^b   Tracy, T S ^c   Romkes, M ^a   Branch, R A ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

CYP2C9; Fluconazole; Flurbiprofen; Inhibitor; Probe drug

Indexed keywords

4' HYDROXYFLURBIPROFEN; CYTOCHROME P450 2C9; DRUG METABOLITE; FLUCONAZOLE; FLURBIPROFEN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG METABOLISM; DRUG SCREENING; DRUG URINE LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; KIDNEY CLEARANCE; MALE; NORMAL HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; ANTIFUNGAL AGENTS; BIOLOGICAL MARKERS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FLUCONAZOLE; FLURBIPROFEN; GENOTYPE; HUMANS; MALE; PHENOTYPE;

EID: 33947247540     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02781.x     Document Type: Article

References (51)

1. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med 2005; 352: 2211-21.
2. Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 1996; 6: 1-42.
3. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992; 44: 2089-98.
4. Frye RF. Probing the world of cytochrome p450 enzymes. Mol Interv 2004; 4: 157-62.
5. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45: 525-38.
6. Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clin Med 2005; 3: 137-45.
7. Taguchi M, Hongou K, Yagi S, Miyawaki T, Takizawa M, Aiba T, Hashimoto Y. Evaluation of phenytoin dosage regimens based on genotyping of CYP2C subfamily in routinely treated Japanese patients. Drug Metab Pharmacokinet 2005; 20: 107-12.
8. Yan Z, Li J, Huebert N, Caldwell GW, Du Y, Zhong H. Detection of a novel reactive metabolite of diclofenac: evidence for CYP2C9-mediated bioactivation via arene oxides. Drug Metab Dispos 2005; 33: 706-13.
9. Niemi M, Cascorbi I, Timm R, Kroemer HK, Neuvonen PJ, Kivisto KT. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes. Clin Pharmacol Ther 2002; 72: 326-32.
10. Kirchheiner J, Brockmoller J. Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther 2005; 77: 1-16.
11. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Differences in flurbiprofen pharmacokinetics between CYP2C9*1/*1, *1/*2, and *1/*3 genotypes. Eur J Clin Pharmacol 2003; 58: 791-4.
12. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000; 10: 187-216.
13. Frye RF, Adedoyin A, Mauro K, Matzke GR, Branch RA. Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 1998; 38: 82-9.
14. Jetter A, Kinzig-Schippers M, Skott A, Lazar A, Tomalik-Scharte D, Kirchheiner J, Walchner-Bonjean M, Hering U, Jakob V, Rodamer M, Jabrane W, Kasel D, Brockmoller J, Fuhr U, Sorgel F. Cytochrome P450 2C9 phenotyping using low-dose tolbutamide. Eur J Clin Pharmacol 2004; 60: 165-71.
15. Tassaneeyakul W, Birkett DJ, Pass MC, Miners JO. Limited value of the urinary phenytoin metabolic ratio for the assessment of cytochrome P4502C9 activity in vivo. Br J Clin Pharmacol 1996; 42: 774-8.
16. Takahashi H, Kashima T, Nomizo Y, Muramoto N, Shimizu T, Nasu K, Kubota T, Kimura S, Echizen H. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes. Clin Pharmacol Ther 1998; 63: 519-28.
17. Geisslinger G, Lotsch J, Menzel S, Kobal G, Brune K. Stereoselective disposition of flurbiprofen in healthy subjects following administration of the single enantiomers. Br J Clin Pharmacol 1994; 37: 392-4.
18. Knadler MP, Brater DC, Hall SD. Stereoselective disposition of flurbiprofen in normal volunteers. Br J Clin Pharmacol 1992; 33: 369-75.
19. Davies NM. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 1995; 28: 100-14.
20. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, Johnson EF. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution. J Biol Chem 2004; 279: 35630-7.
21. Tracy TS, Rosenbluth BW, Wrighton SA, Gonzalez FJ, Korzekwa KR. Role of cytochrome P450 2C9 and an allelic variant in the 4?-hydroxylation of (R)- and (S)-flurbiprofen. Biochem Pharmacol 1995; 49: 1269-75.
22. Tracy TS, Marra C, Wrighton SA, Gonzalez FJ, Korzekwa KR. Studies of flurbiprofen 4′-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 1996; 52: 1305-9.
23. Small RE, Cox SR, Adams WJ. Influence of H2 receptor antagonists on the disposition of flurbiprofen enantiomers. J Clin Pharmacol 1990; 30: 660-4.
24. Kharasch ED, Thummel KE, Mhyre J, Lillibridge JH. Single-dose disulfiram inhibition of chlorzoxazone metabolism: a clinical probe for P450 2E1. Clin Pharmacol Ther 1993; 53: 643-50.
25. Venkatakrishnan K, Von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
26. Cooper KJ, Martin PD, Dane AL, Warwick MJ, Schneck DW, Cantarini MV. The effect of fluconazole on the pharmacokinetics of rosuvastatin. Eur J Clin Pharmacol 2002; 58: 527-31.
27. Tang C, Shou M, Mei Q, Rushmore TH, Rodrigues AD. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 2000; 293: 453-9.
28. Niwa T, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol Pharm Bull 2005; 28: 1805-8.
29. Blum RA, Wilton JH, Hilligoss DM, Gardner MJ, Henry EB, Harrison NJ, Schentag JJ. Effect of fluconazole on the disposition of phenytoin. Clin Pharmacol Ther 1991; 49: 420-5.
30. Kunze KL, Wienkers LC, Thummel KE, Trager WF. Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. Drug Metab Dispos 1996; 24: 414-21.
31. Black DJ, Kunze KL, Wienkers LC, Gidal BE, Seaton TL, McDonnell ND, Evans JS, Bauwens JE, Trager WF. Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. Drug Metab Dispos 1996; 24: 422-8.
32. Kunze KL, Trager WF. Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. Drug Metab Dispos 1996; 24: 429-35.
33. Kaukonen KM, Olkkola KT, Neuvonen PJ. Fluconazole but not itraconazole decreases the metabolism of losartan to E-3174. Eur J Clin Pharmacol 1998; 53: 445-9.
34. Greenblatt DJ, Von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther 2006; 79: 125-33.
35. Hutzler JM, Frye RF, Tracy TS. Sensitive and specific high-performance liquid chromatographic assay for 4′-hydroxyflurbiprofen and flurbiprofen in human urine and plasma. J Chromatogr B Biomed Sci Appl 2000; 749: 119-25.
36. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA. Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes. Clin Pharmacol Ther 1997; 62: 365-76.
37. Chow SC, Liu JP. Design and Analysis of Bioavalability and Bioequivalence Studies. New York: Marcel Dekker, INC., 1992.
38. Tucker GT, Houston JB, Huang SM. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm Res 2001; 18: 1071-80.
39. Veronese ME, Miners JO, Randles D, Gregov D, Birkett DJ. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990; 47: 403-11.
40. Inaba T, Otton SV, Kalow W. Debrisoquine hydroxylation capacity: problems of assessment in two populations. Clin Pharmacol Ther 1981; 29: 218-23.
41. Lee CR, Pieper JA, Frye RF, Hinderliter AL, Blaisdell JA, Goldstein JA. Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans. J Clin Pharmacol 2003; 43: 84-91.
42. Jamali F, Singh NN, Pasutto FM, Russell AS, Coutts RT. Pharmacokinetics of ibuprofen enantiomers in humans following oral administration of tablets with different absorption rates. Pharm Res 1988; 5: 40-3.
43. Albert KS, Gillespie WR, Raabe A, Garry M. Determination of flurbiprofen in human serum by reverse-phase high-performance liquid chromatography with fluorescence detection. J Pharm Sci 1984; 73: 1823-5.
44. Szpunar GJ, Albert KS, Bole GG, Dreyfus JN, Lockwood GF, Wagner JG. Pharmacokinetics of flurbiprofen in man. I. Area/dose relationships. Biopharm Drug Dispos 1987; 8: 273-83.
45. Benvenuti C, Gambaro V, Lodi F, Scaroni C, Bandi G, Valenti M. Single-dose pharmacokinetics of flurbiprofen granules and tablets in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 1989; 27: 334-7.
46. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, Dickmann LJ. Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: effect on atypical kinetic metabolism profiles. Drug Metab Dispos 2002; 30: 385-90.
47. Uchaipichat V, Winner LK, MacKenzie PI, Elliot DJ, Williams JA, Miners JO. Quantitative prediction of in vivo inhibitory interactions involving glucuronidated drugs from in vitro data: the effect of fluconazole on zidovudine glucuronidation. Br J Clin Pharmacol 2006; 61: 427-39.
48. Kuehl GE, Lampe JW, Potter JD, Bigler J. Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos 2005; 33: 1027-35.
49. Sabolovic N, Heydel JM, Li X, Little JM, Humbert AC, Radominska-Pandya A, Magdalou J. Carboxyl nonsteroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 2004; 1675: 120-9.
50. Neal JM, Kunze KL, Levy RH, O'Reilly RA, Trager WF. Kiiv, an in vivo parameter for predicting the magnitude of a drug interaction arising from competitive enzyme inhibition. Drug Metab Dispos 2003; 31: 1043-8.
51. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT. Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics 1996; 6: 121-49.